Folic Acid-d4
(Synonyms: N-[4-[[(2-氨基-1,4-二氢-4-氧代-6-蝶啶)甲基]氨基]苯甲酰基-2,3,5,6-D4]-L-谷氨酸,Vitamin B9-d4; Vitamin M-d4) 目录号 : GC45456
An internal standard for the quantification of folic acid
Cas No.:171777-72-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Folic acid-d4 is intended for use as an internal standard for the quantification of folic acid by GC- or LC-MS. Folic acid is an essential B vitamin.1 It is converted to folate in vivo, which is a necessary cofactor for a variety of biological processes, including nucleotide synthesis and, thus, DNA synthesis and repair, among others. A deficiency in dietary folic acid can lead to a range of developmental and cognitive disorders, most prominently neural tube defects and congenital heart defects.1,2,3
References
1. Czeizel, A.E., DudÁs, I., Vereczkey, A., et al. Folate deficiency and folic acid supplementation: The prevention of neural-tube defects and congenital heart defects. Nutrients 5(11), 4760-4775 (2013).
2. Nair, M.K., Augustine, L.F., and Konapur, A. Food-based interventions to modify diet quality and diversity to address multiple micronutrient deficiency. Front. Public Health 3, 277 (2016).
3. Sarmah, S., Muralidharan, P., and Marrs, J.A. Common congenital anomalies: Environmental causes and prevention with folic acid containing multivitamins. Birth Defects Res. C Embryo Today 108(3), 274-286 (2016).
| Cas No. | 171777-72-3 | SDF | |
| 别名 | N-[4-[[(2-氨基-1,4-二氢-4-氧代-6-蝶啶)甲基]氨基]苯甲酰基-2,3,5,6-D4]-L-谷氨酸,Vitamin B9-d4; Vitamin M-d4 | ||
| Canonical SMILES | O=C1C2=NC(CNC3=C([2H])C([2H])=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C([2H])=C3[2H])=CNC2=NC(N)=N1 | ||
| 分子式 | C19H15D4N7O6 | 分子量 | 445.4 |
| 溶解度 | DMF: 10 mg/ml,DMSO: 20 mg/ml,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2452 mL | 11.2259 mL | 22.4517 mL |
| 5 mM | 0.449 mL | 2.2452 mL | 4.4903 mL |
| 10 mM | 0.2245 mL | 1.1226 mL | 2.2452 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Development and Validation of a Rapid High-Performance Liquid Chromatography⁻Tandem Mass Spectrometric Method for Determination of Folic Acid in Human Plasma
Pharmaceuticals (Basel) 2018 May 27;11(2):52.PMID:29861484DOI:10.3390/ph11020052.
There are health concerns associated with increased folic acid intake from fortified food and supplements. Existing analytical methods, however, which can be employed to carry out epidemiological and bioavailability studies for folic acid involve laborious sample preparation and/or lengthy chromatographic analysis. In this paper we describe a simple, rapid, and sensitive high-performance liquid chromatography⁻electrospray ionisation-tandem mass spectrometry (HPLC⁻ESI-MS/MS) method for determination of unmetabolised folic acid in human plasma using Folic Acid-d4 as an internal standard. The method required only a simple sample preparation step of protein precipitation and had a total run time of 3.5 min, which is the shortest run time reported to date for HPLC⁻MS/MS method employed for quantifying folic acid in plasma. The analytes were separated on a C18 column (3 µm; 50 × 3.00 mm) using an isocratic mobile phase consisting of ammonium acetate (1 mM)-acetic acid-acetonitrile (9.9:0.1:90, v/v/v). The method was fully validated in terms of accuracy, precision, linearity, selectivity, recovery, matrix effect, and stability. The short run time and the minimal sample preparation makes the method a valuable tool for performing high-throughput analyses. To demonstrate the applicability of the method in real conditions, it was applied successfully in a bioavailability study for the determination of unmetabolised folic acid levels in vivo in human plasma after oral administration of folic acid.